Pronostic & traitement

• Essai MITHRIDATE (PHRC-K INCA)
IP: JJ Kiladjian – St Louis, APHP
“A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high-risk polycythemia vera”.(contraintes techniques)
Population : PV/TE JAK2VF+ sans TT cytoréducteur, diag> 1an